Compare UPC & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPC | ADTX |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.1M |
| IPO Year | 2021 | 2020 |
| Metric | UPC | ADTX |
|---|---|---|
| Price | $3.63 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.5K | ★ 1.9M |
| Earning Date | 04-29-2025 | 11-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,293,003.00 | $5,945.00 |
| Revenue This Year | N/A | $15,768.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.51 | $2.15 |
| 52 Week High | $42.80 | $10,119.10 |
| Indicator | UPC | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 37.22 |
| Support Level | $3.95 | $2.20 |
| Resistance Level | $4.54 | $3.75 |
| Average True Range (ATR) | 0.34 | 0.62 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 16.96 | 4.56 |
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.